David focuses his practice on the representation of public and private pharmaceutical, biotechnology, and other life sciences companies with respect to a variety of intellectual property-based commercial transactions, including licenses and research and development collaborations.
Cooley advised Alto Neuroscience, a company redefining psychiatry by leveraging individuals’ neurobiology to develop personalized and highly effective medicines and helping patients get better faster, on its $147.9 million initial public offering.
SystImmune Announces Global Strategic Collaboration With Bristol Myers Squibb
December 11, 2023
Cooley advised SystImmune, a clinical-stage biopharmaceutical company, on its exclusive license and collaboration agreement with Bristol Myers Squibb for SystImmune’s BL-B01D1.
Cooley advised Alto Neuroscience, a company pioneering precision psychiatry by developing targeted medicines designed to help patients get better faster, on its oversubscribed $45 million Series C financing round.
Cooley advised Immatics, a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, on its strategic collaboration with Moderna.
